RecruitingBorderline Resectable/Unresectable Pancreatic CancerNon Metastatic Pancreatic Cancer
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
Sponsor: University of Arkansas
You may qualify if…
- ✓ 1. Age ≥ 18 years.
- ✓ 2. Pathologically proven locally advanced adenocarcinoma of pancreas.
- ✓ 3. Borderline resectable pancreatic cancer that is determined to be unresectable following completion of SoC chemotherapy and RT as evidenced by any of the following:
- ✓ 1. Encasement of gastroduodenal artery up to the common hepatic artery/short segment encasement or abutment of the hepatic artery, but without extension to the celiac trunk.
- ✓ 2. Venous involvement of SMV or portal vein, less than 180 degrees.
- ✓ 3. Tumor abutment of SMA, less than half the circumference of the vessel wall. OR
- ✓ Unresectable pancreatic cancer that remains unresectable following completion of SoC chemotherapy and RT as evidenced by any of the following:
- ✓ 4. Greater than 180-degree encasement or occlusion/thrombus of SMA, unresectable SMV, or SMV-portal confluence occlusion.
You may not qualify if…
- ✕ 1. Pancreatic cancer that was either resectable before SoC treatment or became resectable following SoC chemotherapy and RT.
- ✕ 2. Subjects with radiographically proven metastatic disease are excluded.
- ✕ 3. Subject must not be pregnant and/or currently breastfeeding or plan to be.
- ✕ 4. Subject must not have received any live vaccine, including MMR, within 30 days prior to the dose of study drug.
- ✕ 5. Subject must not have treatment with any anti-cancer therapy including chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents, within 5 half-lives (or 2 weeks if half-life is unknown) prior to day 1.
- ✕ 6. Subject has no unresolved toxicities, AEs ≥ Grade 2 (NCI CTCAE version 5.0), from prior anticancer therapy.
- ✕ 7. Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.
Where it's recruiting
Arkansas
Little Rock
Source: ClinicalTrials.gov · NCT07539155 · last updated 2026-09-01